1 / 19

Sildenafil

Sildenafil. Speaker : Chin–Hsiang Tu 2008.12.23. Sildenafil (Viagra). 膜衣錠 50 mg. 膜衣錠 100 mg. 化學式 : 1-〔4-ethoxy-3-(6,7-dihydro-1-methl-7-oxo-3-propyl-1H-pyrazolo〔4,3-d〕pyrimidin-5-yl) phenylsulphonyl〕-4-methylpiperazine citrate. 實驗式 : C 22 H 30 N 6 O 4 S.C 6 H 8 O. 分子量 : 666.7.

ctims
Download Presentation

Sildenafil

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Sildenafil Speaker : Chin–Hsiang Tu 2008.12.23

  2. Sildenafil (Viagra) 膜衣錠50 mg 膜衣錠100 mg

  3. 化學式 : 1-〔4-ethoxy-3-(6,7-dihydro-1-methl-7-oxo-3-propyl-1H-pyrazolo〔4,3-d〕pyrimidin-5-yl) phenylsulphonyl〕-4-methylpiperazine citrate 實驗式 :C22H30N6O4S.C6H8O 分子量 :666.7 Sildenafil Viagra 威而鋼

  4. Pharmacology • Viagra是一種口服有效，且對 cGMP-specific PDE5(phosphodiesterase type 5)具有選擇性的抑制劑。 • PDE5主要存在於平滑肌組織中。 • Viagra 藉由抑制 PDE5避免 cGMP 被分解成 GMP, 來達到治療 Penis erectile dysfunction. NATURE REVIEWS | DRUG DISCOVERY VOLUME 5 | AUGUST 2006 | 689

  5. Designing history • Origins of the cGMP/PDE3 project at Pfizer in the mid-1980s. Ex. Minipress, Cardura …… • Nitrate act as mixed dilators of arteries and veins. • The therapeutic potential of nitrates is limited by the rapid induction of tachyphylaxis. (是一種矛盾現象,會產生跟原來目的完全相反的效果) • In 1986 Pfizer with the aim of developing a selective inhibitor of PDE5 and evaluating its preclinical pharmacology.

  6. In 1989 UK-92,480 was selected to undergo further development and entered clinicaltrials in 1991. • In 1992, volunteers also reported penile erections as a side effect. • In mid-1993, UK-92,480 was looking less promising as a new treatment . • In 1998 , approval of sildenafil as Viagra by FDA as first oral treatment for erectile dysfunction.

  7. Designing model • Zaprinast • Developed as an anti-allergy compound • Non-selective • Similar size, shape and dipoles • Intramolecular hydrogen bond forms planar strucuture

  8. (1.) Pyrazolopyrimidinones

  9. (2.) Pyrazole substitution

  10. (3.) Phenyl substitution • Need to reduce lipophilicity, increase solubility Groups chosen to reduce log D , and maximum solubility.

  11. (4.) Preferred compound

  12. 3D structure of PDE5 complex with sildenafil

  13. Preclinical Pharmacology - Vessels Effect of sildenafil verse nitrate on nerve stimulated contraction of blood vessels in vivo.

  14. Preclinical Pharmacology - Corp. Cav. Effect of sildenafil on electrical field stimulated relaxation of human corpus cavernosum Sildenafil dose-dependently enhances relaxation of corpus cavernosum

  15. Preclinical Pharmacology - Platelet Effect of sildenafil on anti-aggregation action of SNP Sildenafil has no direct effect on agonist-induced aggregation

  16. Tadalafil Cialis 犀利士 Vardenafil Levitra 樂威壯 Sildenafil Viagra 威而鋼

  17. Market for drugs to treat ED Expecting sales of ED therapies in the major markets to nearly double during the next several years, reaching US $3.5 billion in 2013. In that year, combined sales of tadalafil and vardenafil will account for more than 50% market share. NATURE REVIEWS | DRUG DISCOVERY VOLUME 3 | APRIL 2004 | 295

More Related